ArticleInternational journal of molecular sciences2020
A Novel Peptide Antibiotic, Pro10-1D, Designed from Insect Defensin Shows Antibacterial and Anti-Inflammatory Activities in Sepsis Models.
Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- Phospholipid-Coated FeAntibiotics (Basel, Switzerland) · 2026Article
- Advances of Antimicrobial Peptides in the Treatment of Multidrug-Resistant Bacteria.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Cationic antimicrobial peptide CC34 potential anticancer and apoptotic induction on cancer cells.Amino acids · 2025Article
- Antimicrobial Peptide Pro10-1D Exhibits Anti-Allergic Activity: A Promising Therapeutic Candidate.International journal of molecular sciences · 2024Article
- Bioactive Peptides and Other Immunomodulators of Mushroom Origin.Biomedicines · 2024Review
- Time dependent changes in protein expression induced by intermittent theta burst stimulation in a cell line.Frontiers in neurology · 2024Article
- Protective Effects of Rhamnetin in Carbapenem-ResistantInternational journal of molecular sciences · 2023Article
- Bioactive Peptides from Edible Mushrooms-The Preparation, Mechanisms, Structure-Activity Relationships and Prospects.Foods (Basel, Switzerland) · 2023Review
- Characterization of the Antimicrobial Activities ofPharmaceutics · 2023Article
- Creation of New Antimicrobial Peptides.International journal of molecular sciences · 2023Article
- Resistance, Tolerance, Virulence and Bacterial Pathogen Fitness-Current State and Envisioned Solutions for the Near Future.Pathogens (Basel, Switzerland) · 2023Review
- Microflora for improving theiScience · 2022Article
- Antimicrobial potentials of natural products against multidrug resistance pathogens: a comprehensive review.RSC advances · 2022Review
- Novel D-form of hybrid peptide (D-AP19) rapidly kills Acinetobacter baumannii while tolerating proteolytic enzymes.Scientific reports · 2022Article
- Detecting the Mechanism of Action of Antimicrobial Peptides by Using Microscopic Detection Techniques.Foods (Basel, Switzerland) · 2022Review
- Antiseptic 9-Meric Peptide with Potency against Carbapenem-ResistantInternational journal of molecular sciences · 2021Article
- Development of Novel Peptides for the Antimicrobial Combination Therapy against Carbapenem-ResistantPharmaceutics · 2021Article
- Gram-Negative Bacteria Holding Together in a Biofilm: TheMicroorganisms · 2021Review
- Study of the ultrastructure of Enterococcus faecalis and Streptococcus mutans incubated with salivary antimicrobial peptides.Clinical and experimental dental research · 2021Article
- Insect antimicrobial peptides: potential weapons to counteract the antibiotic resistance.Cellular and molecular life sciences : CMLS · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Owing to the challenges faced by conventional therapeutics, novel peptide antibiotics against multidrug-resistant (MDR) gram-negative bacteria need to be urgently developed. We had previously designed Pro9-3 and Pro9-3D from the defensin of beetle
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.